---
schema_version: "secwatch.filing_event.v1"
accession: "0000886744-25-000007"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T10:14:39.663736+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Geron Q1: RYTELO revenue $39.4M; demand flat; EU approval granted for LR-MDS

## Summary
- RYTELO net product revenue $39.4M in Q1 2025; demand up only 1% vs prior 13 weeks due to inventory drawdown.
- European Commission granted marketing authorization for RYTELO; launch in select EU countries planned for 2026.
- Phase 3 IMpactMF trial for R/R myelofibrosis ~85% enrolled; interim OS analysis expected 2H 2026.
- Net loss improved to $19.8M ($0.03/share) vs $55.4M ($0.09/share) in Q1 2024 on first product revenue.
- FY2025 total operating expense guidance maintained at $270M-$285M; cash $457.5M as of March 31.

## SEC filing metadata
- accession: 0000886744-25-000007
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/0000886744-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/gern-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886744-25-000007
- JSON: https://secwatch.observer/filing/0000886744-25-000007.json
- Plain text: https://secwatch.observer/filing/0000886744-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.